Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Anti-PD-1, and P-GemOx in R/R NKTCL
NCT06573151Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selinexor in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Ruijin Hospital. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06573151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573151.